Bone metastases detection by circulating biomarkers: OPG and RANK-L

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 255-261

  Mercatali, Laura ^a   Ibrahim, Toni ^a   Sacanna, Emanuele ^a   Flamini, Emanuela ^a   Scarpi, Emanuela ^a   Calistri, Daniele ^a   Ricci, Marianna ^a   Serra, Patrizia ^a   Ricci, Rossana ^a   Zoli, Wainer ^a   Kang, Yibin ^b   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

Bone metastases; Breast cancer; Diagnosis; Osteoprotegerin; Receptor activator of nuclear factor B ligand

Indexed keywords

BIOLOGICAL MARKER; CANCER ANTIGEN 15-3; CARCINOEMBRYONIC ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE NEOPLASMS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HT29 CELLS; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND; RETROSPECTIVE STUDIES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 79956004585     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1001     Document Type: Article

References (29)

1. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593, 2002.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
3. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243S-6249S, 2006.
4. Lipton A, Cook R, Saad F, et al: Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113: 193-201, 2008. (Pubitemid 351976401)
5. Doggrell SA: Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Rev Anticancer Ther 9: 1211-1218, 2009.
6. Stopeck A, Body JJ, Fujiwara Y, et al: Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer 7 (Suppl): 2, 2009.
7. Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999. (Pubitemid 29168945)
8. Hof bauer LC, Neubauer A and Heufelder AE: Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92: 460-470, 2001.
9. Blair JM, Zhou H, Seibel MJ and Dunstan CR: Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3: 41-49, 2006.
10. Mori K, Ando K, Heymann D and Redini F: Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histol Histopathol 24: 235-242, 2009.
11. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D and Rabbani SA: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107: 289-298, 2006. (Pubitemid 44036558)
12. Mountzios G, Dimopoulos MA, Bamias A, et al: Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46: 221-229, 2007.
13. Coleman R Brown J, Terpos E, et al: Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34: 629-639, 2008.
14. Coleman RE: The role of bone markers in metastatic bone disease. Cancer Treat Rev 32 (Suppl 1): 1-2, 2006.
15. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE and Delmas PD: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82: 858-864, 2000. (Pubitemid 30085239)
16. Ulrich U, Rhiem K, Schmolling J, et al: Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264: 186-190, 2001. (Pubitemid 32105009)
17. Jung K, Lein M, Stephan C, et al: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783-791, 2004. (Pubitemid 39062904)
18. Ricotti L, Barzanti F, Tesei A, et al: Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures. Ann Oncol 11: 587-594, 2000. (Pubitemid 30431382)
19. Gonnelli S, Cadirni A, Caffarelli C, et al: Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40: 205-210, 2007. (Pubitemid 44839329)
20. Coleman RE, Major P, Lipton A, et al: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925-4935, 2005. (Pubitemid 46223998)
21. Costelloe CM, Rohren EM, Madewell JE, et al: Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10: 606-614, 2009.
22. Pestalozzi B and Castiglione M: Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 (Suppl 2): 7-10, 2008.
23. Ben-Haim S and Israel O: Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 39: 408-415, 2009.
24. Ebert W, Muley T, Herb KP and Schmidt-Gayk H: Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24: 3193-3201, 2004. (Pubitemid 39390972)
25. Nicolini A, Tartarelli G, Carpi A, et al: Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 6: 269, 2006.
26. Nicolini A, Carpi A and Tarro G: Biomolecular markers of breast cancer. Front Biosci 11: 1818-1843, 2006.
27. Clamp A, Danson S, Nguyen H, Cole D and Clemons M: Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5: 607-616, 2004. (Pubitemid 39303128)
28. Costa L, Demers LM, Gouveia-Oliveira A, et al: Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850-856, 2002. (Pubitemid 34111395)
29. Kiuchi K, Ishikawa T, Hamaguchi Y, et al: Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep 9: 595-598, 2002.